This inventor holds 4 USPTO granted patents, plus 1 CIPO patent. Top assignee: Incyte Corporation. Active years: 2006-2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2006-2014
Title: The Innovations of Eddy Wai Tsun Yue
Introduction
Eddy Wai Tsun Yue is a notable inventor based in Landenberg, PA, who has made significant contributions to the field of pharmaceuticals. With a total of four patents to his name, he has focused on developing innovative compounds that have the potential to treat various diseases.
Latest Patents
One of his latest patents is titled "Macrocyclic compounds and their use as kinase inhibitors." This invention relates to macrocyclic compounds of Formula I, or pharmaceutically acceptable salts thereof, which serve as JAK/ALK inhibitors. These compounds are particularly useful in treating JAK/ALK-associated diseases, including inflammatory and autoimmune disorders, as well as cancer. Another significant patent is "N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase." This invention focuses on N-hydroxyamidino compounds that act as modulators of indoleamine 2,3-dioxygenase (IDO), along with their compositions and pharmaceutical methods.
Career Highlights
Eddy is currently employed at Incyte Corporation, where he continues to work on groundbreaking research and development in the pharmaceutical industry. His expertise in creating innovative compounds has positioned him as a valuable asset to his team and the company.
Collaborations
Eddy has collaborated with several talented individuals, including Andrew Paul Combs and Richard B Sparks. These partnerships have allowed for the exchange of ideas and the advancement of their collective research efforts.
Conclusion
Eddy Wai Tsun Yue's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving healthcare. His work continues to pave the way for new treatments and therapies that can benefit many patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
